## **AMENDMENTS TO THE CLAIMS**

The following listing of claims will replace all prior versions and listings of claims in the application.

## **LISTING OF CLAIMS**

1-6. (Cancelled)

Please add the following new claims:

- 7. (NEW) A method for treatment of a subject, comprising using a pharmaceutical composition containing a medication and a viscoelastic substance in surgery of a cavity of the subject, the cavity having been inherently aseptic.
- 8. (NEW) The method for treatment of a subject according to claim 7, wherein said viscoelastic substance is selected from a group consisting of hyaluronic acid, nontoxic salts thereof, chondroitin sulfuric acid, nontoxic salts thereof, hydroxypropyl methylcellulose and a mixture of these compounds.
- 9. (NEW) The method for treatment of a subject according to claim 7, wherein said medication is selected from a group consisting of anti-inflammatory agents and antimicrobial agents.
- 1,0. (NEW) The method for treatment of a subject according to claim 7, wherein said medication is an antimicrobial agent and said viscoelastic substance is a mixture of sodium hyaluronate and chondroitin sulfuric acid.
- 11. (NEW) A method for treatment of a subject, comprising using a pharmaceutical composition containing a medication and a viscoelastic substance in an internal ocular surgery of the subject.

- 12. (NEW) The method for treatment of a subject according to claim 11, wherein said viscoelastic substance is selected from a group consisting of hyaluronic acid, nontoxic salts thereof, chondroitin sulfuric acid, nontoxic salts thereof, hydroxypropyl methylcellulose and a mixture of these compounds.
- 13. (NEW) The method for treatment of a subject according to claim 11, wherein said medication is selected from a group consisting of anti-inflammatory agents and antimicrobial agents.
- 14. (NEW) The method for treatment of a subject according to claim 11, wherein said medication is an antimicrobial agent and said viscoelastic substance is a mixture of sodium hyaluronate and chondroitin sulfuric acid.
- 15. (NEW) The method for treatment of a subject according to claim 11, wherein the subject suffers from cataract.
- 16. (NEW) The method for treatment of a subject according to claim 11, wherein the internal ocular surgery is selected from a group consisting of cataract surgery, glaucoma surgery, corneal transplantation and vitrectomy.
- 17. (NEW) A method for treatment of a subject, comprising using a pharmaceutical composition containing a medication and a viscoelastic substance in surgery of an articular joint space of the subject.
- 18. (NEW) The method for treatment of a subject according to claim 17., wherein said viscoelastic substance is selected from a group consisting of hyaluronic acid, nontoxic salts thereof, chondroitin sulfuric acid, nontoxic salts thereof, hydroxypropyl methylcellulose and a mixture of these compounds.

- 19. (NEW) The method for treatment of a subject according to claim 1.7, wherein said medication is selected from a group consisting of anti-inflammatory agents and antimicrobial agents.
- 20. (NEW) The method for treatment of a subject according to claim 17, wherein said medication is an antimicrobial agent and said viscoelastic substance is a mixture of sodium hyaluronate and chondroitin sulfuric acid.
- 21. (NEW) A method for preservation against an infection of an internal ocular space in a postoperative subject, comprising using a pharmaceutical composition containing a medication and a viscoelastic substance to the internal ocular space in a surgical operation.
- 22. (NEW) The method for preservation against an infection of an internal ocular space in a postoperative subject according to claim 21, wherein the surgical operation is selected from a group consisting of cataract surgery, glaucoma surgery, corneal transplantation and vitrectomy.